Bartholomew Beth A, Harjai Kishore J, Dukkipati Srinivas, Boura Judith A, Yerkey Michael W, Glazier Susan, Grines Cindy L, O'Neill William W
Division of Cardiology, William Beaumont Hospital, Royal Oak, Michigan 48073, USA.
Am J Cardiol. 2004 Jun 15;93(12):1515-9. doi: 10.1016/j.amjcard.2004.03.008.
Radiocontrast-induced nephropathy (RCIN) after percutaneous coronary intervention (PCI) is associated with grave consequences, but risk stratification of patients has not been well elucidated. This analysis derived a time-insensitive score to predict the risk of RCIN after PCI. A derivation cohort (1993 to 1998) and a validation cohort (1999 to 2002) comprised 20,479 patients who underwent PCI. RCIN after PCI was defined as a >/=1.0 mg/dl increase in serum creatinine. Variables having an independent correlation for RCIN after PCI were used to derive the RCIN risk score from the derivation cohort and were tested in the validation cohort. RCIN occurred in 2% of patients after PCI. Independent variables (with weighted scores) include estimated creatinine clearance <60 ml/min (2), urgent PCI (2), intra-aortic balloon pump use (2), diabetes mellitus (1), congestive heart failure (1), hypertension (1), peripheral vascular disease (1), and contrast volume >260 ml (1). The incidence of RCIN after PCI increased with each unit increase in score (p <0.0001, concordance statistic 0.89). No patient with a score </=1 developed nephropathy, whereas 26% of patients with a score >/=9 developed RCIN after PCI (p <0.0001). Propensity score analysis showed that patients who developed RCIN after PCI, irrespective of the need for hemodialysis, had higher in-hospital rates of major adverse cardiac events (odds ratio 15, 95% confidence interval 11 to 20, p <0.0001). RCIN occurred in 2.0% of PCI patients and was associated with a 15-fold increase in adverse cardiac events. The RCIN risk score was a clinical assessment tool with excellent predictive ability in identifying the larger population at risk for nephropathy in whom preventative strategies are indicated.
经皮冠状动脉介入治疗(PCI)后发生的造影剂肾病(RCIN)会带来严重后果,但患者的风险分层尚未得到很好的阐明。本分析得出了一个不依赖时间的评分,以预测PCI后发生RCIN的风险。一个推导队列(1993年至1998年)和一个验证队列(1999年至2002年)包括20479例行PCI的患者。PCI后RCIN定义为血清肌酐升高≥1.0mg/dl。将PCI后与RCIN具有独立相关性的变量用于从推导队列中得出RCIN风险评分,并在验证队列中进行检验。PCI后2%的患者发生了RCIN。独立变量(加权评分)包括估计肌酐清除率<60ml/min(2分)、急诊PCI(2分)、使用主动脉内球囊泵(2分)、糖尿病(1分)、充血性心力衰竭(1分)、高血压(1分)、外周血管疾病(1分)和造影剂用量>260ml(1分)。PCI后RCIN的发生率随评分每增加一个单位而升高(p<0.0001,一致性统计量0.89)。评分≤1分的患者无一人发生肾病,而评分≥9分的患者中26%在PCI后发生了RCIN(p<0.0001)。倾向评分分析显示,PCI后发生RCIN的患者,无论是否需要血液透析,其住院期间主要不良心脏事件的发生率较高(比值比15,95%置信区间11至20,p<0.0001)。2.0%的PCI患者发生了RCIN,且不良心脏事件增加了15倍。RCIN风险评分是一种临床评估工具,在识别需要采取预防策略的更大肾病风险人群方面具有出色的预测能力。